At present, a variety of EGFR inhibitors targeting TNBC are used in the clinical treatment of breast cancer, such as the tyrosine kinase inhibitors afatinib, erlotinib and lapatinib, as well as monoclonal antibodies such as cetuximab and panitumumab [6]. Here, EGFR is linked to breast cancer.